This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs Therapy.

Lazertinib is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.

This is a Multi-center, Prospective, Early Access Program of Lazertinib in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with T790M mutation-positive after 1st/2nd generation EGFR TKIs therapy to assess the safety and efficacy of real world evidence as second-line treatment.

Inclusion Criteria:

• Patients aged at least 19 years
• Patients who have written consent for use of personal and medical information for the study purpose
• Patients who are prescribed and administered with approved indication for Lazerinib in Korea and not been treated with Lazertinib previously.

Exclusion Criteria:

• Patients with hypersensitivity to Lazertinib or its any ingredients
• Patients who belong to contraindication listed on lazertinib label in Korea
• Patients who are treated for an indication not approved for the use of Lazertinib
• Women who are pregnant or may possibly become pregnant